Search results for " Liver neoplasm"

showing 10 items of 78 documents

Does access to care play a role in liver cancer survival? The ten-year (2006–2015) experience from a population-based cancer registry in Southern Ita…

2021

Abstract Background Hepatocellular carcinoma (HCC) is the most frequent primary invasive cancer of the liver. During the last decade, the epidemiology of HCC has been continuously changing in developed countries, due to more effective primary prevention and to successful treatment of virus-related liver diseases. The study aims to examine survival by level of access to care in patients with HCC, for all patients combined and by age. Methods We included 2018 adult patients (15–99 years) diagnosed with a primary liver tumour, registered in the Palermo Province Cancer Registry during 2006–2015, and followed-up to 30 October 2019. We obtained a proxy measure of access to care by linking each re…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAdolescentContext (language use)access to care cancer registries liver cancer public health survival Adolescent AdultAge Distribution Aged Aged 80 and over Carcinoma Hepatocellular Decision Making Organizational Decision Support Techniques Female Follow-Up Studies Health Services Accessibility Health Services Needs and Demand Humans Italy Liver Neoplasms Male Middle Aged Registries Survival Analysis Young AdultSettore MED/42 - Igiene Generale E Applicatalcsh:RC254-282survivalHealth Services AccessibilityDecision Support Techniquesliver cancerYoung AdultAge DistributionInternal medicineHealth careEpidemiologyGeneticsmedicineHumansRegistriesDecision Making OrganizationalAgedAged 80 and overaccess to careHealth Services Needs and Demandbusiness.industryPublic healthLiver Neoplasmspublic healthMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisCancer registryItalyOncologycancer registriesHepatocellular carcinomaAmbulatoryFemaleLiver cancerbusinessFollow-Up StudiesResearch ArticleBMC Cancer
researchProduct

Focal nodular hyperplasia-like lesions in patients with cavernous transformation of the portal vein: prevalence, MR findings and natural history.

2011

PURPOSE: To retrospectively investigate the prevalence, MR findings, natural history, and association with other hepatic lesions of focal nodular hyperplasia (FNH)-like lesions in a cohort of consecutive patients with cavernous transformation of the portal vein (CTPV). MATERIALS AND METHODS: This retrospective IRB-approved study comprised 58 patients (32 men, 26 women; average age, 50 years) with CTPV who underwent liver MR imaging between 2000 and 2008. MR images were assessed by two radiologists in consensus for the presence of (a) FNH-like lesions and other liver lesions, and (b) other imaging findings. Patients were assigned to a stable or progressive clinical course based on lesion cha…

AdultMalemedicine.medical_specialtyAbdomen Liver Cavernous transformation of the portal vein Benign liver neoplasms Magnetic resonance imagingAdenomaLesionHemangiomaCohort StudiesReference ValuesmedicineImage Processing Computer-AssistedHumansRadiology Nuclear Medicine and imagingLiver focal nodular hyperplasia cavernomatosis portal veinNeuroradiologyAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryPortal VeinLiver NeoplasmsFocal nodular hyperplasiaMagnetic resonance imagingInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureTreatment OutcomeFocal Nodular HyperplasiaAbdomenFemaleRadiologymedicine.symptombusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaEuropean radiology
researchProduct

Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

2015

OBJECTIVES:The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the BCLC B stage reclassification in a large cohort of patients with untreated HCC managed by the Italian Liver Cancer Group.METHODS:We assessed the prognosis of 269 untreated HCC patients observed in the period 1987-2012 who were reclassified according to the proposed subclassification of the BCLC B stage from stage B1 to stage B4. We evaluated and compa…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularPrognosiAdult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Young Adult; GastroenterologyGastroenterologyIntermediate stage03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineCarcinoma80 and overHumansProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overHepatologybusiness.industryMedicine (all)Settore MED/09 - MEDICINA INTERNACarcinomaLiver NeoplasmsGastroenterologyHepatocellularMiddle Agedmedicine.diseasePrognosisProspective StudieLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm stagingFemaleLiver cancerbusinessHuman
researchProduct

CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA

2015

Background CD90+ liver cancer cells have been described as cancer stem-cell-like (CSC), displaying aggressive and metastatic phenotype. Using two different in vitro models, already described as CD90+ liver cancer stem cells, our aim was to study their interaction with endothelial cells mediated by the release of exosomes. Methods Exosomes were isolated and characterized from both liver CD90+ cells and hepatoma cell lines. Endothelial cells were treated with exosomes, as well as transfected with a plasmid containing the full length sequence of the long non-coding RNA (lncRNA) H19. Molecular and functional analyses were done to characterize the endothelial phenotype after treatments. Results …

Cancer ResearchAngiogenesisAngiogenesis; CD90+ liver cancer cells; Exosomes; Long-non-coding RNA H19; Antigens Thy-1; Cell Adhesion; Cell Line Tumor; Endothelial Cells; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; RNA Long Noncoding; Phenotype; Molecular Medicine; Oncology; Cancer ResearchBiologyCD90+ liver cancer cellsExosomesCell LineSettore BIO/13 - Biologia ApplicataCancer stem cellCell Line TumormedicineCell AdhesionHuman Umbilical Vein Endothelial CellsHumansCD90AntigensThy-1TumorExosomes Long-non-coding RNA H19 CD90+ liver cancer cells AngiogenesisResearchLiver NeoplasmsCancerEndothelial Cellsmedicine.diseaseMicrovesiclesCell biologyEndothelial stem cellPhenotypeOncologyembryonic structuresThy-1 AntigensRNAMolecular MedicineRNA Long NoncodingLong NoncodingAngiogenesisStem cellLiver cancerLong-non-coding RNA H19Molecular Cancer
researchProduct

Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediatedviathe extrinsic and the intrinsic pathway

2010

We investigated the downstream mechanisms by which chemotherapeutic drugs elicit apoptosis in hepatocellular carcinoma (HCC). Genomic signatures of HCC cell lines treated with different chemotherapeutic drugs were obtained. Analyses of apoptosis pathways were performed and RNA interference was used to evaluate the role of the p53 family. Endogenous p53, p63 and p73 were upregulated in response to DNA damage by chemotherapeutic drugs. Blocking p53 family function led to chemoresistance in HCC. Stimulation and blocking experiments of the CD95-, the TNF- and the TRAIL-receptor systems revealed that cytotoxic drugs, via the p53 family members as transactivators, can trigger expression of each o…

Cancer ResearchProgrammed cell deathCarcinoma HepatocellularTumor suppressor geneDNA damagetumor suppressor protein p53membrane proteinsoligonucleotide array sequence analysiscarcinomaBiologyhepatocellularfas-associated death domain proteinAPAF1humansMembrane Potential Mitochondrialhep G2 cellsbleomycinliver neoplasmsSettore BIO/11apoptosisPrognosismitochondrialFas receptorcaspasesOncologyApoptosisbiology.proteinCancer researchMdm2membrane potentialSignal transductionPrognosis; bleomycin; caspases; membrane potential mitochondrial; oligonucleotide array sequence analysis; tumor suppressor protein p53; membrane proteins; fas-associated death domain protein; humans; liver neoplasms; hep G2 cells; apoptosis; carcinoma hepatocellularInternational Journal of Cancer
researchProduct

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

2018

Abstract Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat w…

HCV; WHO; chronic infection; linkage to careLiver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSustained Virologic ResponseViral HepatitisSettore MED/12 - GASTROENTEROLOGIAWorld Health OrganizationAntiviral AgentsNO03 medical and health sciencesLiver diseaseWHO0302 clinical medicinePharmacotherapyCost of IllnessCause of DeathHealth caremedicineHumans030212 general & internal medicineViremiachronic infection HCV linkage to care WHODisease EradicationMortalityIntensive care medicineCause of deathlinkage to carechronic infection; HCV; linkage to care; WHODisease EradicationHepatologybusiness.industryPublic healthCarcinomaLiver NeoplasmsHepatocellularHepatitis Cmedicine.diseasechronic infectionHepatitis CMarkov Chainschronic infection; HCV; linkage to care; WHO; Antiviral Agents; Carcinoma Hepatocellular; Cost of Illness; Disease Eradication; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Mortality; Sustained Virologic Response; Viremia; World Health Organization; Cause of DeathItalychronic infection;HCV;linkage to care;WHOHCVchronic infection; HCV; linkage to care; WHO; Hepatology030211 gastroenterology & hepatologybusinessViral hepatitis
researchProduct

Rare ATG7 genetic variants predispose patients to severe fatty liver disease

2022

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci that contribute to severe NAFLD by examining rare variants.Methods: We performed whole-exome sequencing in in-dividuals with NAFLD and advanced fibrosis or hepatocellular carcinoma (n = 301) and examined the enrichment of likely pathogenic rare variants vs. the general population. This was followed by validation at the gene level.Results: In patients with severe NAFLD, we observed an enrichment of the p.P426L variant (rs143545741 C>T; odds ratio [OR] 5.26, 95% CI 2.1-12.6; p = 0.003) of autophagy-rela…

InflammationLiver CirrhosisautophagyHepatologyBiopsyNAFLD NASH autophagy genetics liver fibrosisCarcinomaLiver NeoplasmsNASHHepatocellularAutophagy-Related Protein 7NAFLD; NASH; autophagy; genetics; liver fibrosis; Autophagy-Related Protein 7; Biopsy; Humans; Inflammation; Liver; Liver Cirrhosis; Carcinoma Hepatocellular; Liver Neoplasms; Non-alcoholic Fatty Liver DiseaseLiverNon-alcoholic Fatty Liver DiseaseNAFLDHumansgeneticsgeneticautophagy; genetics; liver fibrosis; NAFLD; NASHliver fibrosis
researchProduct

Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease

2015

It has been shown that sexual hormones have an opposite effect on hepatic fibrosis progression and hepatocellular carcinoma development. Sex differences among 2,762 chronic HBsAg carriers consecutively referring Italian hospitals in 2001 and in 2007 have been evaluated, particularly focusing on the role of gender on severity of liver disease. The overall sex ratio (males/females) was 2.6. Females were more likely born abroad and new diagnosis cases; but less likely HIV coinfected. No sex difference was observed regarding coinfection with other hepatitis viruses. The sex ratio linearly increased with increasing severity of liver disease, being 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6…

Liver CirrhosisAdultMaleChronic HBsAg carriers; Cirrhosis; Hepatocellular carcinoma; Sex differences; Adult; Aged; Carcinoma Hepatocellular; Female; Hepatitis B Surface Antigens; Hepatitis B Chronic; Humans; Italy; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Sex Factors; Virology; Infectious DiseasesCarcinoma HepatocellularHepatocellular carcinomaLiver CirrhosiHepatitis B Surface AntigenChronic HBsAg carriersHepatitis B ChronicSex FactorsVirologySex differencesHumansChronicAgedChronic HBsAg carrierHepatitis B Surface AntigensCirrhosiCarcinomaLiver NeoplasmsHepatocellularMiddle AgedHepatitis BSex differenceInfectious DiseasesCirrhosisItalyLiverLiver NeoplasmFemaleHuman
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct

Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the…

2020

Abstract Background The COVID-19 pandemic had a huge impact on national and regional health systems. The impact of SARS-CoV-2 on the quality of care for patients with liver disease is still unknown. Aims The Italian Association for the Study of the Liver (AISF) conducted a survey to assess the impact of SARS-CoV-2 on hepatology units activities in Italy. Methods A prospective web-based survey was proposed to all AISF active members. The survey was available online from April 8 2020, to May 3 2020, (lockdown phase in Italy). Results 194 AISF members answered the questionnaire, most of whom were specialists in Gastroenterology (41%) or Internal Medicine (28%), and worked in Northern Italy (51…

Liver CirrhosisLiver disease0302 clinical medicineSurveys and QuestionnairesPandemicAmbulatory CareMass ScreeningParacentesisViralChronicLiver DiseasesLiver NeoplasmsGastroenterologyHepatology Covid-19 SARS COV-2Hepatitis BHepatitis CHospitalizationCovid-19; Hepatology; SARS COV-2Italy030220 oncology & carcinogenesis030211 gastroenterology & hepatologyCoronavirus Infectionsmedicine.medical_specialtyCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralEsophageal and Gastric VaricesAntiviral AgentsArticle03 medical and health sciencesBetacoronavirusHepatitis B ChronicInternal medicinemedicineHumansPandemicsMass screeningQuality of Health CareHepatologybusiness.industrySARS-CoV-2SARS COV-2CarcinomaOutbreakCOVID-19HepatocellularPneumoniaHepatitis C ChronicHepatologymedicine.diseaseNorthern italyLiver TransplantationEmergency medicineChronic DiseaseCovid-19; Hepatology; SARS COV-2; Ambulatory Care; Antiviral Agents; Betacoronavirus; COVID-19; Carcinoma Hepatocellular; Chronic Disease; Coronavirus Infections; Esophageal and Gastric Varices; Gastroenterology; Hepatitis B Chronic; Hepatitis C Chronic; Hospitalization; Humans; Italy; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Liver Transplantation; Mass Screening; Pandemics; Paracentesis; Pneumonia Viral; Quality of Health Care; SARS-CoV-2; Surveys and Questionnairesbusiness
researchProduct